Prosecution Insights
Last updated: August 06, 2026

Mucpharm Pty Ltd.

3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready

Portfolio Summary

3
Total Pending OAs
0
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)3 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
IANNUZO, NATALIE NMN 1 13.5% +83.3%
FAN, LYNN Y 1 47.5% +48.7%
FERNANDEZ, SUSAN EMILY 1 52.3% +60.9%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18007134 COMPOSITIONS AND METHODS FOR TREATING BACTERIAL INFECTIONS IANNUZO, NATALIE NMN 16d
17922709 PREVENTING AND TREATING VIRAL INFECTIONS FAN, LYNN Y
16975058 FORMULATIONS CONTAINING MUCIN-AFFECTING PROTEASES FERNANDEZ, SUSAN EMILY

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18007134 COMPOSITIONS AND METHODS FOR TREATING BACTERIAL INFECTIONS IANNUZO, NATALIE NMN 16d
17922709 PREVENTING AND TREATING VIRAL INFECTIONS FAN, LYNN Y
16975058 FORMULATIONS CONTAINING MUCIN-AFFECTING PROTEASES FERNANDEZ, SUSAN EMILY

Top Art Units

Art UnitApps
1653 1
1759 1
1651 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18007134 COMPOSITIONS AND METHODS FOR TREATING BACTERIAL INFECTIONS IANNUZO, NATALIE NMN 1653 §102§103 Final Rejection 16d Pending Jan 27, 2023
17922709 PREVENTING AND TREATING VIRAL INFECTIONS FAN, LYNN Y 1759 §103§112 Final Rejection Pending Nov 01, 2022
16975058 FORMULATIONS CONTAINING MUCIN-AFFECTING PROTEASES FERNANDEZ, SUSAN EMILY 1651 §103§112Other Final Rejection Pending Aug 21, 2020

Managing Mucpharm Pty Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month